Patents by Inventor Christopher John Arthur Finnis

Christopher John Arthur Finnis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140031294
    Abstract: The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein.
    Type: Application
    Filed: July 29, 2013
    Publication date: January 30, 2014
    Applicant: Novozymes Biopharma DK A/S
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Joanna Hay
  • Publication number: 20130244277
    Abstract: The present invention provides a host cell suitable for enhanced production of a protein product of choice characterised in that the host cell is genetically modified to cause over-expression of two or more helper proteins selected from a DnaJ-like protein (such as JEM1), an Hsp70 family protein (such as LHS1) and SIL1, wherein at least one of the over-expressed two or more helper proteins is selected from JEM1, LHS1 and SIL1, and wherein the DnaJ-like protein is not SCJ1.
    Type: Application
    Filed: March 4, 2013
    Publication date: September 19, 2013
    Applicants: UNIVERSITY OF NOTTINGHAM, NOVOZYMES BIOPHARMA DK A/S
    Inventors: Thomas Payne, Darrell Sleep, Christopher John Arthur Finnis, Leslie Robert Evans
  • Publication number: 20120231505
    Abstract: The present invention provides a method for producing a desired protein (such as a desired heterologous protein) comprising: (a) providing a host cell comprising a first recombinant gene encoding a protein comprising the sequence of a first chaperone protein, a second recombinant gene encoding a protein comprising the sequence of a second chaperone protein and a third gene, such as a third recombinant gene, encoding a desired protein (such as a desired heterologous protein), wherein the first and second chaperones are different; and (b) culturing the host cell in a culture medium to obtain expression of the first, second and third genes.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 13, 2012
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Gillian Shuttleworth
  • Publication number: 20120231503
    Abstract: The present disclosure relates to a method for producing heterologous protein including: (c) providing a host cell comprising a 2 ?m-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein; (d) culturing the host cell in a culture medium under conditions that allow the expression of the gene encoding the chaperone protein and the gene encoding a heterologous protein; (e) purifying the thus expressed heterologous protein from the cultured host cell or the culture medium.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 13, 2012
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Gillian Shuttleworth, Christopher John Arthur Finnis
  • Patent number: 8252551
    Abstract: The present invention provides a 2 ?m-family plasmid comprising a polynucleotide sequence insertion, deletion and/or substitution between the first base after the last functional codon of at least one of either a REP2 gene or an FLP gene and the last base before the FRT site in an inverted repeat adjacent to said gene.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: August 28, 2012
    Assignee: Novozymes Biopharma DK A/S
    Inventors: Darrell Sleep, Christopher John Arthur Finnis
  • Publication number: 20110313133
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Application
    Filed: February 11, 2010
    Publication date: December 22, 2011
    Applicants: Novozymes A/S, Novozymes BioPharma DK A/S
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Jason Cameron, Darrell Sleep
  • Publication number: 20110020865
    Abstract: The present invention provides a host cell suitable for enhanced production of a protein product of choice characterised in that the host cell is genetically modified to cause over-expression of two or more helper proteins selected from a DnaJ-like protein (such as JEM1), an Hsp70 family protein (such as LHS1) and SIL1 wherein at least one of the over-expressed two or more helper proteins is selected from JEM1, LHS1 and SIL1, and wherein the DnaJ-like protein is not SCJ1.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 27, 2011
    Applicants: Novozymes Delta Limited, University of Nottigham
    Inventors: Thomas Payne, Darrell Sleep, Christopher John Arthur Finnis, Leslie Robert Evans
  • Publication number: 20100222267
    Abstract: The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein.
    Type: Application
    Filed: June 13, 2008
    Publication date: September 2, 2010
    Applicant: Novozymes Biopharma UK Limited.
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Joanna Hay
  • Publication number: 20080261861
    Abstract: The present invention provides a 2 ?m-family plasmid comprising a polynucleotide sequence insertion, deletion and/or substitution between the first base after the last functional codon of at least one of either a REP2 gene or an FLP gene and the last base before the FRT site in an inverted repeat adjacent to said gene.
    Type: Application
    Filed: December 23, 2004
    Publication date: October 23, 2008
    Applicant: DELTA BIOTECHNOLOGY LIMITED
    Inventors: Darrell Sleep, Christopher John Arthur Finnis
  • Publication number: 20080193977
    Abstract: The present invention provides a method for producing a desired protein (such as a desired heterologous protein) comprising: (a) providing a host cell comprising a first recombinant gene encoding a protein comprising the sequence of a first chaperone protein, a second recombinant gene encoding a protein comprising the sequence of a second chaperone protein and a third gene, such as a third recombinant gene, encoding a desired protein (such as a desired heterologous protein), wherein the first and second chaperones are different; and (b) culturing the host cell in a culture medium to obtain expression of the first, second and third genes.
    Type: Application
    Filed: December 23, 2005
    Publication date: August 14, 2008
    Applicant: Novozymes Delta Limited
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Gillian Shuttleworth